Showing 1271-1280 of 1918 results for "".
- Skyrizi Performs Well in Phase 3 Studies of PsAhttps://practicaldermatology.com/news/skyrizi-performs-well-in-phase-3-studies-of-psa/2460647/Two Phase 3 studies of Risankizumab (Skyrizi) show improvements in disease activity across joint and skin symptoms in patients with psoriatic arthritis. KEEPsAKE-1 and KEEPsAKE-2 found that significantly more patients treated with risankizumab (150 mg) achieved the primary end
- Katie Cheng Is Cynosure's New CMOhttps://practicaldermatology.com/news/katie-cheng-is-cynosures-new-cmo/2460646/Katie Cheng is Cynosure’s new Chief Marketing Officer. "Katie's proven track record of consumer and professional marketing strategy and execution is one of the many reasons we are eager to have Katie join our team," says Cynosure CEO Todd Tillemans, i
- Metabolic Syndrome Linked to Higher Cardiovascular Risk in Psoriasis Patientshttps://practicaldermatology.com/news/metabolic-syndrome-linked-to-higher-cardiovascular-risk-in-psoriasis-patients/2460645/Metabolic syndrome in people with psoriasis may contribute to an increased risk of heart disease, according to a study in the Journal of the American Association of Dermatology. &ldqu
- Breaking News: AbbVie’s Allergan Wins Trade Secret Case Against Evolushttps://practicaldermatology.com/news/breaking-news-abbvies-allergan-wins-trade-secret-case-against-evolus/2460635/AbbVie Inc.’s Allergan won a U.S. trade agency order to block Evolus Inc. and its partner Daewoong Pharmaceutical Co. from importing Jeuveau into the U.S. for 21 months, according to media reports. The U.S. International Trade Commission upheld a judge’s findings that Jeuvea
- Are Sunscreens Overstating Their SPF?https://practicaldermatology.com/news/are-sunscreens-overstating-their-spf/2460629/One out of 12 sunscreens worldwide are likely overstating their sun protection factor, according to research from What’s In My Jar, a London-based AI-powered skincare startup. Using machine learning, What’s In My Jar analyzed formulas of 1,205 sunscreen products in thei
- Revlon Names Martine Williamson As Chief Marketing Officerhttps://practicaldermatology.com/news/revlon-names-martine-williamson-as-its-chief-marketing-officer/2460625/Martine Williamson is Revlon’s new Chief Marketing Officer. In this role, Williamson will be central to creating and spearheading global strategic plans across the brand portfolio and overseeing Revlon’s overall brand equity and architecture. Williamson officially join
- L'Oréal's SkinCeuticals Taps New GMhttps://practicaldermatology.com/news/loreals-skinceuticals-taps-new-gm/2460621/Stephanie Kramer is L'Oréal's SkinCeuticals new General Manager. Kramer was Global Senior Vice President of Marketing, Product Innovation and Retail at SkinCeuticals. Prior to joining SkinCeuticals in 2019, Kramer served as Vice President of Global Marketi
- Study: Iron Oxides Offer Protection Skin from Blue Lighthttps://practicaldermatology.com/news/study-iron-oxides-protection-skin-from-blue-light/2460616/Iron oxides provide enhanced protection against HEV or blue light, especially when combined with zinc oxide, according to results of a new study in The Journal of Cosmetic Dermatology. HEV
- Research Identifies Long-Term Benefits of Incorporating Ceramides into Baby Skincarehttps://practicaldermatology.com/news/research-identifies-long-term-benefits-of-incorporating-ceramides-into-baby-skincare/2460612/Using ceramide-infused products on baby skin may have long-term benefits lasting into adulthood, according to a newly published study in the Journal of Drugs in Dermatology. Beyond n
- More Positive Phase 3 Data for Pfizer's Abrocitinib in ADhttps://practicaldermatology.com/news/more-positive-phase-3-data-for-pfizers-abrocitinib-in-ad/2460607/Positive top-line results from the phase 3 JADE REGIMEN study offer additional data in support of Pfizer's investigational oral once-daily Janus kinase 1 (JAK1) inhibitor for atopic dermatitis (AD). The 52-week study looked at patients 12 and older wi